Financing HIV/Aids in South Africa and role of major donors Meeting to inform Council for Foreign Relations January 2010 Mark Blecher National Treasury.

Slides:



Advertisements
Similar presentations
Resource requirements for reaching the treatment goals under PEPFAR XV International AIDS Conference Bangkok July 15, 2004 Owen Smith, Abt Associates Inc.
Advertisements

Spending on ART by Provinces in South Africa: trends, cost drivers, (in)efficiencies and sustainability Simelela, N., Sipho, S., Sozi, C., Damisoni, H.,
PEPFAR’s Approach to Maximize Efficiency, Effectiveness and Impact
Overview of the Global Fund: Guiding Principles Grant Cycle / Processes & Role of Public Private Partnerships Johannesburg, South Africa Tatjana Peterson,
Taking Another Look at Condoms Patrick Friel Reproductive Health HIV/AIDS Consultancy 27 April 2006.
AIDS2031 LONG TERM COSTS AND FINANCING FOR HIV/AIDS ICAAP 12 AUGUST 2009 BALI INDONESIA Farzana Muhib, Results for Development Institute.
Burden of malaria and other infectious diseases in the Asia-Pacific Ravi P. Rannan-Eliya Institute for Health Policy Sri Lanka.
HEALTH AND HIV FUNDING Budget Monitoring Forum Presenter: Mark Blecher | National Treasury | November 2011.
Presentation to the 2014 International AIDS Conference
Financial Implications of HIV/AIDS in South Africa – the role of the Business Sector Findings from aids2031 costing & the efforts of the National AIDS.
Implemented by KZN Department of Public Works
The Polity Utility of Tracking State HIV/AIDS Allocations UNAIDS Satellite Meeting: “National AIDS Accounts” XV International AIDS Conference Bangkok,
Quality Improvement Capacity for Impact Project (QICIP) Pre-Review Conference Call Competitive Funding Opportunity Announcement: HRSA March 25,
HIV and the Financial Crisis Academic Council Debate on the Financial Crisis and Public Health Robert Greener, April 30, 2009.
Access to HIV/AIDS, Tuberculosis and Malaria Medicines. WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies. Geneva, 18 – 22 September.
1 DEPARTMENT OF SOCIAL DEVELOPMENT PRESENTATION TO THE SELECT COMMITTEE ON FINANCE ON THE PROVINCIAL BUDGETS & EXPENDITURE REVIEW 14 NOVEMBER 2006.
Concept Note on HIV Mongolia Process and key components of Funding Request to Global Fund.
Teresa Guthrie M.PH (Health Economics) HIV modelling for in-country ownership solutions – generation of evidence IAS Conference, Washington DC, July.
HIV NON-INTERVENTION: A COSTLY OPTION A NEW FRAMEWORK FOR GLOBALIZATION Jeffrey D. Sachs, PhD Director, Center for International Development Galen L. Stone.
‘More Than Just Lip Service: Scaling up sex work initiatives’ Making the Money Matter: Support for sex worker initiatives through the Global Fund for HIV,
1 NATIONAL DEPARTMENT OF HEALTH PRESENTATION ON THE FFC RECOMMENDATIONS ON THE DIVISION OF REVENUE 2011/12 17 AUGUST 2010.
Budget Hearings: Social Development Committee By Macharia Kamau Representative, UNICEF South Africa 28 February 2007.
Washington D.C., USA, July 2012www.aids2012.org Estimating the Costs and Impacts of HIV/AIDS Programs for Botswana Examples of the ART Program and.
Financing the response to HIV in low- and middle-income countries: how it is affected by the economic crisis? Robert Greener July 20, 2011.
Macro Effects of Scaling Up Aid: A Case Study of Tanzania Mick Foster.
Accelerating Africa’s Growth and Development to meet the Millennium Development Goals: Emerging Challenges and the Way Forward Presentation on behalf of.
Debbi Birx, MD PEPFAR/CDC WORKSHOP - Mini Room 7 Center for Global Health Division of Global HIV/AIDS Getting to Six Million PEPFAR Track 1.0 Treatment.
Enabling Continuity of a Public Health ARV Treatment program in a resource limited setting: The Case of the transition of the African Comprehensive HIV/AIDS.
1 World Health Organization, Geneva Identifying human resources information needs for ART programmes World Health Organization Human Resources for Health.
HIV & AIDS FUNDING AND ECONOMIC RECESSION: A CALL FOR VISIONARY LEADERSHIP International AIDS Conference Vienna, 2010 Vailet Mukotsanjera-Kowayi: HEAD:
MKUKUTA/PER Consultations 2007 DPG session MKUKUTA/PEFAR 22 May.
SAG-USG Joint 5-Year Partnership Framework (PF) and Partnership Framework Implementation Plan (PFIP) 2012/13 – 2016/17 KwaZulu Natal SAG PEPFAR All Partners’
The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department.
Doc ID SABCOHA STRATEGY MEETING 13 OCTOBER 2011 LESSONS LEARNT FROM THE HCT CAMPAIGN Intensifying our efforts to achieve the Millennium Development Goals.
Downloaded from Current Status of ART Opportunities & Challenges Kibrebeal Melaku,MD Associate Professor.
2015/10/261 NATIONAL DEPARTMENT OF HEALTH PRESENTATION TO THE STANDING COMMITTEE ON APPROPRIATIONS 2009 MEDUIM TERM BUDGET POLICY STATEMENT (MTBPS) 30.
1 Domestic Financing for Health Parliamentarian Round Table March 2014,Joburg, SA Linda Mafu, Head Political Advocacy and Civil Society Department,
Western Cape Wellness Summit 08 November 2011 Infectious Diseases.
1 2009/10 DIVISION OF REVENUE BILL Presentation to Select Committee on Finance 24 February 2009.
DEVELOPMENT PARTNERS GROUP (DPG) SPECIAL BRIEFING SESSION ON HIV&AIDS 5 OCTOBER 2006 By DPG AIDS 1.
World Health Organization "3 by 5" Target Treat 3 million by 2005.
The National HIV Counselling and Testing Campaign and Treatment Expansion in South Africa: A return on investments in combination prevention XIX International.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.
Strengthening HIV/AIDS Programs Through Multisectoral Approaches Ishrat Z. Husain USAID/Bureau for Africa Office of Sustainable Development PHN Officers’
External Relations and Partnerships Harmonization and Coordination Experiences of the Global Fund.
Efficiency, Effectiveness, and Financial Sustainability: The Importance of Country Ownership Dr Bernhard Schwartländer UNAIDS.
Getting more value for money: working with countries and partners toward greater effectiveness and efficiency Peter Stegman, Senior Economist.
Provincial Budgets and Expenditure Review: 2003/04 – 2009/10 Chapter 3: Health 17 October 2007.
1 Financing Tourism Development Owen Willcox | Chief Director: Economic Services, National Treasury 31 March 2015.
SELECT COMMITTEE ON APPROPRIATION HEARING ON DIVISION OF REVENUE BILL B
EPWP Phase II Portfolio Committee Cape Town Feb 2009.
Presentation to: the Joint Budget Committee on the Medium Term Budget Policy Statement Employment & Social Security November 19, 2003 Dr. Miriam Altman.
World Vision Experiences in Making ART Treatment Affordable and Available Dr. Daniel J Malleboyina M.B.B.S, MBA, MPH Regional Advisor HIV & AIDS- Asia.
The Bank’s Regional HIV/AIDS Strategies An Overview.
Implementing operational research for HIV treatment scale-up in resource-limited settings TB/HIV Research Priorities in Resource-Limited Settings Expert.
Ministry of Public Health & Population Haiti Toward Universal Care HIV/AIDS October 2010.
ARV Treatment Scale Up: Progress in Ukraine Andriy Klepikov Executive Director, International HIV/AIDS Alliance in Ukraine ARV Treatment Scale Up: Progress.
Presentation to the Health Portfolio Committee Presentation to Health Portfolio Committee Free State Department of Health 15 APRIL 2003.
Demanding a high impact HIV response: civil society advocacy and the President’s Emergency Plan for Aids Relief (PEPFAR) Dorothy Namutamba International.
HIV and AIDS The management of HIV and AIDS is an ongoing challenge for Anglo companies operating in countries with a high burden of HIV disease Strategy.
IFC 2008 Creating Opportunity.
Current harm reduction program at outreach
Expanding ARV treatment in developing countries: Issues and Prospects
HIV Response Funding Trends 10:30 am to 12:00 pm
Jeffrey D. Sachs, PhD Director, Center for International Development
PRESENTATION TO THE SELECT COMMITTEE ON FINANCE 18 OCTOBER 2005
July 21, 2016 Potential Domestic Source Financing for Scaled Up Antiretroviral Therapy in 97 Countries, 2016–2020 Arin Dutta, Catherine Barker, and Ashley.
Financial Implications of HIV/AIDS in South Africa – the role of the Business Sector Findings from aids2031 costing & the efforts of the National.
Background: 2 primary vehicles to transfer funds to provinces from national: conditional grants & equitable share Problems with condtl grants (underspending)
Presentation transcript:

Financing HIV/Aids in South Africa and role of major donors Meeting to inform Council for Foreign Relations January 2010 Mark Blecher National Treasury Keith Cloete WC DOH

2 Scale of problem SA has largest number of HIV infected persons in world >5m Largest number of persons on treatment Number of persons on treatment growing rapidly – will exceed pa in 10/11 Soon to exceed 1 mil on treatment but this will grow to over 3 million new infections pa with prevention programmes not sufficiently effective Highest spending of any country on HIV ….but this will need to triple over time Huge implications for struggling health services

3 HIV costing NSP costing suggested scenarios of R11b-R13b per annum by 2011 New draft costing by aids2031 suggest costs could reach R40 billion by 2030 This includes other sectors and private – but amounts are huge – could rise from 18% to 40% of health budget And these don’t fully factor costs of lower treatment threshold of cd4 350 Need to continue to strive to reduce unit costs

4 NSP: Summarized total costs for the low cost scenarios (million Rands, 2005/06 prices)

Aids 2031 Draft scenario

Projected growth in number of ART patients if 80% target is met (Dorrington)

Financing Both graphs (cost and number of arvs) level off Once level off govt can fully carry costs However period from 2010 to 2015 is one of v rapid scale-up Esp given lower treatment thresholds, move to 80% coverage, improved prevention …..and many other health sector issues and priorities Require >R2bil new funds annually during scale-up Difficult to sustain this level of scale-up and simultaneously replace existing donor funding 8

Some major financing streams 09/10 approximate 9

Two broad positions of donors 1) Middle income countries must look after themselves or 2) Very high burden of disease middle income countries merit support We support second option. SA has little need for donors beyond HIV, but the HIV problem is very large and difficult Sustainable as govt will take over funding as treatment numbers start stabilising Govt has sought partnership with major donors eg PEPFAR and Global Fund 10

Major donors Pepfar and Global Fund have played major role in SA Especially helped to build capacity through supporting govt treatment points Supported large numbers of worthy projects Amounts are large and partnership is valuable Donors potentially bring technical expertise, flexibility, support 11

Problem areas Value for money huge amounts being spent – are we getting best value – we may have sufficient funds if we optimally used the combined pool Weak coordination between provincial and donor funded services Fragmentation between large numbers of organisations poorly coordinated Difficulty aligning services and funding coming via multiple routes Difficulty allocating tasks and funding around a common plan 12

Potential improvements Build shared commitment around common plan and agreement on division of work –responsibilities, services and funding Funding on budget (WC Global Fund) worked v well Would be good to develop a five year plan and clear partnership (there is huge amount to do – scale up to 3 m on Rx) 13

Western Cape case study

Scenarios for uptake of ART in the Western Cape Province (assuming guideline change for ART eligibility to 350 cells/µl) Current financial year

Background The Current (Expiring) Western Cape GF Grant Programme –R–Round 3 (originally 5-year grant) –S–Sub-CCM: Western Cape Provincial AIDS Council Title: Strengthening & Expanding the Western Cape HIV/AIDS Prevention, Treatment & Care Programme Four Objectives in the Grant Programme 1.ARV treatment services 2.Peer education HIV prevention intervention in selected secondary schools 3.Palliative care services 4.Community Based Response (small grants programme to local CBOs/NGOs) Special circumstances of Western Cape Phase 2 Grant Programme –4–4-year Phase 2 period in respect of Objectives 1 & 3 in order to provide for a Grant exit strategy (funding ends June 2010) –3–3-year Phase 2 period in respect of Objectives 2 & 4 (funding ended June 2009)

ARV Treatment Services – Western Cape Costing Model –Revised normative staffing model for medical, nursing, pharmacy, clerical & adherence support (NGO) staff Task shifting/sharing First year’s treatment norms vs norms for subsequent years 2009 public service salary scales + 7% inflator p.a. –Revised model for patients on first & second line ARV treatment All patients start on first line Average of 0.2% per month changed to second line –Average ARV medicine cost/patient In 2009: First line: R215 p.m.; Second line: R642 p.m. Constant unit cost/patient over RCC period –Lab tests (NHLS): CD4 Count & Viral Load 6 monthly tests per patient (ART Protocol) Average 5% p.a. inflator over RCC period

W CAPE RCC PROPOSAL DEVELOPMENT Addressing Long Term Financial Sustainability –Government’s ability to meet the funding requirements of the Western Cape HIV/AIDS Programme (from own revenue sources) has been seriously affected by the global economic downturn since –Problem is likely to persist over the coming MTEF period, followed by economic & fiscal recovery. –RCC Proposal is therefore structured in order to: Request maximum possible Grant funding for Years 7 – 9 Followed by incremental transfer of Grant Programme activities to government funding sources in Years 10 – 12

Conclusion HIV treatment and prevention will need to scale up massively over next years This has huge cost implications – spending doubling to tripling However ultimately sustainable as numbers and costs level off Partnership and support will be valuable during this period of rapid scale-up There are many advantages to developing an improved partnership arrangement over next 5+ years We value support that has been given and would hope to see an ongoing and strengthened partnership for next 5 years 19